PANTHERx Rare Pharmacy Company Profile
Background
Founded in 2011, PANTHERx Rare Pharmacy is a specialty pharmacy dedicated exclusively to rare and orphan diseases. Headquartered in Pittsburgh, Pennsylvania, the company operates nationwide, providing access to orphan products and comprehensive support services for individuals with rare and devastating conditions. PANTHERx's mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare diseases. The company's vision is to set the standard for the rare pharmacy industry by empowering individuals living with rare diseases to experience the moments in life most important to them. PANTHERx has been recognized multiple times for its commitment to patient care, including being a seven-time winner of the MMIT Patient Choice Award.
Key Strategic Focus
PANTHERx focuses on providing personalized support and access solutions for individuals with rare diseases. The company specializes in distributing orphan products and offers comprehensive patient support services through its RxARECARE® programs. PANTHERx leverages innovative technology and a patient-centric approach to streamline access to rare medications, aiming to improve health outcomes and reduce overall healthcare costs. The primary markets targeted include patients, healthcare providers, pharmaceutical manufacturers, and payers involved in the rare disease ecosystem.
Financials and Funding
In July 2022, PANTHERx was acquired by an investor consortium consisting of The Vistria Group, Nautic Partners, and General Atlantic. Following the acquisition, Nick Loporcaro, Senior Operating Partner at The Vistria Group, was appointed as Board Chairman. This strategic investment aims to enhance PANTHERx's capabilities and expand its reach in the rare disease pharmacy sector.
Pipeline Development
PANTHERx collaborates with pharmaceutical manufacturers to distribute orphan products and provide access and support services to patients. The company has been selected as the exclusive specialty pharmacy for various treatments, including ZILBRYSQ® (zilucoplan) for generalized myasthenia gravis and Filsuvez® (birch triterpenes) topical gel. These partnerships demonstrate PANTHERx's commitment to expanding its portfolio and providing access to innovative therapies for rare diseases.
Technological Platform and Innovation
PANTHERx distinguishes itself through its proprietary RxARECARE® programs, which offer disease-specific clinical support and personalized patient care. The company utilizes innovative technology to streamline access to rare medications and enhance patient outcomes. PANTHERx's approach includes:
- Proprietary Technologies: Development of customized solutions tailored to the unique needs of rare disease patients.
- Scientific Methodologies: Implementation of comprehensive clinical services associated with life-transforming therapies.
These innovations contribute to PANTHERx's reputation as a leader in the rare disease pharmacy sector.
Leadership Team
PANTHERx's executive team combines extensive industry experience to drive the company's mission and strategic initiatives:
- Bansi Nagji: Chief Executive Officer
With over 25 years of leadership experience in pharma services and healthcare technology, Bansi Nagji has held positions such as President of Healthcare at GoodRx and Executive Vice President at McKesson Corporation. He joined PANTHERx as Executive Chair in December 2023 and became CEO in July 2024.
- Rob Snyder, PharmD, MBA, CSP: Executive Chair
A co-founder of PANTHERx in 2011, Dr. Snyder has led the organization through significant growth and transformation. He holds a Doctor of Pharmacy and an MBA from the University of Pittsburgh.
- David Loschinskey: Chief Operating Officer
Bringing over 20 years of specialty pharmacy experience, David oversees technology teams and supports innovation in PANTHERx's technology roadmap. His background includes roles at Advanced Dermatology and Cosmetic Surgery and Diplomat Pharmacy.
- Dana Hand: Chief Human Resource Officer
Dana leads the Human Resources organization, focusing on talent acquisition, leadership development, and employee engagement. She has over 20 years of experience across various industries, including healthcare.
- Arik Moav: Chief Financial Officer
Arik partners with the Board and executive team to shape and execute the company's financial strategies. His experience spans corporate finance and strategy in healthcare and technology sectors.
- Samantha Borden: Chief Legal Officer
Samantha provides legal oversight, ensuring compliance and mitigating risk. Her background includes roles at Diplomat Pharmacy and extensive experience in healthcare law.
- Richard Faris, Ph.D., R.Ph.: Chief Strategy and Growth Officer
Richard is responsible for business development, program management, and clinical innovation. He has been with PANTHERx for over six years and has prior experience at DaVita Rx and Accredo.
Leadership Changes
In July 2022, following the acquisition by The Vistria Group and partners, Nick Loporcaro was appointed as Board Chairman. Nick brings decades of expertise from his roles at McKesson and Landmark Health.
Competitor Profile
Market Insights and Dynamics
The rare disease specialty pharmacy market is characterized by a growing number of orphan drug approvals and an increasing focus on personalized patient care. With over 7,000 identified rare diseases affecting approximately 25 to 30 million Americans, the demand
